Sam Brusco, Associate Editor05.30.23
Resonetics announced that Kevin Kelly will join the company as its new president and CEO, effective May 30. Current president and CEO Tom Burns is retiring and will become executive chairman.
"We are all delighted to welcome Kevin as Resonetics' next CEO. I've known Kevin for more than 20 years, and he brings a long track record of success in the medical technology industry, a customer-centric orientation, and a very collaborative leadership style," Burns told the press. "He has all the attributes to ensure Resonetics will continue to lead the way with the innovative technologies and strong execution our customers require. I'd also like to thank Chip Hance for his mentorship over the past five years as Executive Chairman. He will continue to play an important role as an active member of the board."
"I am excited to be joining Resonetics at this pivotal time," said Kelly. "The pending acquisition of the SAES Medical Nitinol business, combined with Resonetics' robust organic growth, sound industry fundamentals, and strong financial backing, has the company well-positioned for future growth. I look forward to working with the Resonetics team, and our equity investors Carlyle and GTCR, to continue to build a best-in-class offering that will benefit our customers and patients worldwide."
Before Resonetics, Kelly was president of Becton Dickinson’s Surgery business unit. Other prior experiences include leadership roles at C.R. Bard, SmartPill (acquired by Medtronic), LeMaitre Vascular, and MedSource Technologies (now Integer).
"We are all delighted to welcome Kevin as Resonetics' next CEO. I've known Kevin for more than 20 years, and he brings a long track record of success in the medical technology industry, a customer-centric orientation, and a very collaborative leadership style," Burns told the press. "He has all the attributes to ensure Resonetics will continue to lead the way with the innovative technologies and strong execution our customers require. I'd also like to thank Chip Hance for his mentorship over the past five years as Executive Chairman. He will continue to play an important role as an active member of the board."
"I am excited to be joining Resonetics at this pivotal time," said Kelly. "The pending acquisition of the SAES Medical Nitinol business, combined with Resonetics' robust organic growth, sound industry fundamentals, and strong financial backing, has the company well-positioned for future growth. I look forward to working with the Resonetics team, and our equity investors Carlyle and GTCR, to continue to build a best-in-class offering that will benefit our customers and patients worldwide."
Before Resonetics, Kelly was president of Becton Dickinson’s Surgery business unit. Other prior experiences include leadership roles at C.R. Bard, SmartPill (acquired by Medtronic), LeMaitre Vascular, and MedSource Technologies (now Integer).